Zayo 100 Tablet contains a combination of Sacubitril 49 mg and Valsartan 51 mg, formulated for the management of heart failure. Sacubitril is a neprilysin inhibitor that enhances the levels of natriuretic peptides, promoting vasodilation, natriuresis, and diuresis, thereby reducing cardiac workload. Valsartan, an angiotensin II receptor blocker (ARB), inhibits the effects of angiotensin II, leading to vasodilation and decreased aldosterone secretion, which collectively lower blood pressure and reduce cardiac remodeling. The synergistic action of these two agents in Zayo 100 improves cardiovascular outcomes by reducing the risk of hospitalization and mortality in patients with heart failure with reduced ejection fraction (HFrEF). This medication is indicated for adult patients diagnosed with chronic heart failure and is typically prescribed alongside other standard therapies. Dosage and administration should be individualized based on patient tolerance, renal function, and clinical response, with careful monitoring for potential adverse effects such as hypotension, hyperkalemia, and renal impairment. Zayo 100 should be used cautiously in patients with a history of angioedema or severe renal or hepatic dysfunction. Regular follow-up and laboratory assessments are recommended to ensure therapeutic efficacy and safety.